Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Sells $13,762.32 in Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Mark Lackner sold 4,411 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.12, for a total value of $13,762.32. Following the completion of the transaction, the insider now owns 191,317 shares of the company’s stock, valued at $596,909.04. The trade was a 2.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $3.24 on Monday. The stock’s 50-day moving average is $3.33 and its two-hundred day moving average is $3.50. Zentalis Pharmaceuticals, Inc. has a 1 year low of $2.66 and a 1 year high of $18.07. The firm has a market cap of $230.90 million, a price-to-earnings ratio of -1.30 and a beta of 1.84.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. As a group, research analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current year.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently bought and sold shares of the business. GSA Capital Partners LLP boosted its stake in shares of Zentalis Pharmaceuticals by 138.5% during the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after buying an additional 353,384 shares during the period. Decheng Capital LLC lifted its position in Zentalis Pharmaceuticals by 46.2% during the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after acquiring an additional 970,859 shares during the period. XTX Topco Ltd grew its stake in shares of Zentalis Pharmaceuticals by 1,581.9% in the 2nd quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock valued at $730,000 after purchasing an additional 167,854 shares during the last quarter. Verition Fund Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after purchasing an additional 951,500 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Zentalis Pharmaceuticals by 152.6% during the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after purchasing an additional 399,745 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts recently issued reports on ZNTL shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Guggenheim decreased their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, Oppenheimer reissued an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.